Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

167.06 -0.49 (-0.29%)

Streaming Delayed Price Updated: 10:40 AM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

56 57 Next >

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

May 15, 2023

From Biogen Inc.

Via GlobeNewswire

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says. ↗

May 15, 2023

An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.

Via Investor's Business Daily

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win ↗

May 14, 2023

There's no rule that says a market must have only one winner.

Via The Motley Fool

3 Reasons to Buy Biogen Stock (and 1 to Sell) ↗

May 12, 2023

The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.

Via The Motley Fool

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors ↗

May 12, 2023

The biotech's prospects continue to get brighter.

Via The Motley Fool

(BIIB) - Analyzing Biogen's Short Interest ↗

May 10, 2023

Via Benzinga

P/E Ratio Insights for Biogen ↗

May 08, 2023

Via Benzinga

Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8 ↗

May 08, 2023

Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move.

Via Talk Markets

Biogen Unusual Options Activity ↗

May 05, 2023

Via Benzinga

Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal ↗

May 11, 2023

Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.

Via The Motley Fool

Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗

May 09, 2023

Via Benzinga

Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen ↗

May 04, 2023

Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of

Via Benzinga

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

May 03, 2023

Via Benzinga

Why Eli Lilly Stock Is Bolting Higher Today ↗

May 03, 2023

Lilly's Alzheimer's disease candidate might be a best-in-class option for patients.

Via The Motley Fool

Biogen Unusual Options Activity For May 03 ↗

May 03, 2023

Via Benzinga

Looking At Biogen's Recent Unusual Options Activity ↗

April 28, 2023

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗

April 26, 2023

Via Benzinga

Biogen Earnings Perspective: Return On Capital Employed ↗

April 26, 2023

Via Benzinga

These Analysts Revise Price Targets On Biogen Following Q1 Results ↗

April 26, 2023

Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter.

Via Benzinga

Another Sucess In Alzheimer’s Disease ↗

May 03, 2023

Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?

Via Talk Markets

Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises ↗

May 03, 2023

Eli Lilly is focusing on proteins associated with Alzheimer's disease.

Via Investor's Business Daily

Microsoft, Snap And 2 Other Stocks Insiders Are Selling ↗

May 03, 2023

The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Biotech Is Back With Guggenheim Upgrade: What You Need To Know ↗

May 01, 2023

Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock ↗

May 01, 2023

Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2023

Via Benzinga

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy ↗

April 28, 2023

Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023

Via InvestorPlace

Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗

April 26, 2023

The FDA approved Biogen Inc's (NASDAQ:

Via Benzinga

Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

April 26, 2023

Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in...

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today